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Aim. The obtaining of bioaffinity sorbent based on the immobilized protein A of S. aureus (SPA) using two
cellulose-binding domains (CBD), and its application for purification of antibodies. Methods. The DNA
sequences encoding SPA and two CBD were genetically fused, expressed in the high-productive Escherichia coli 
system and the protein SPA-CBD2 was obtained in a soluble form. The SPA-CBD2 fusion protein was affinity
immobilized on the microcrystalline cellulose. Results. Capacity of bioaffinity sorbent (1 mg SPA-CBD2/1 ml
CC31-cellulose), dynamic capacity (3 mg mouse IgG/1 ml bioaffinity sorbent), efficiency and stability during
prolonged storage were determined. The bioffinity sorbent was used for purification of antibodies. The purity of
antibodies in eluted fractions was more than 95 %. The purified antibodies detected target antigens with a high
sensitivity. Conclusions. The designed bioaffinity sorbent provides obtaining pure poly- and monoclonal
antibodies in functionally active form and can be use- ful for the fractionation of mouse immunoglobulin G.
Keywords: antibodies, protein A, cellulose-binding domain, protein immobilization, affinity chromato-
graphy.
Introduction. At present antibodies are widely used in
biomedical practice and in fundamental researches.
The combinations of specific methods are usually used
to obtain considerable amounts of antibodies with high
purity degree; in particular, this is precipitation with
ethanol and different kinds of chromatography: ion-ex- 
change, hydrophobic and metal ion affinity chroma-
tography [1]. However, these methods are not specific,
moreover, the application of some of them results in
partial loss of the functional activity of antibodies. A
highly efficient method of obtaining antibodies is
affinity chromatography with the application of
sorbents on the basis of immobilized immuno-glo-
bulin-binding proteins, in particular recombinant
protein A of Staphylococcus aureus (SPA). This me-
thod is widely used for obtaining fractions of purified
antibodies out of cultural and ascitic fluid, blood sera as 
well as for immunoadsorption of antibodies and circu-
lating immune complexes from blood plasma [2–4].
The specificity of SPA composition, ensuring
specific binding of different species of animals and
humans to IgG, is the presence of five domains (E, D,
A, B, C), each of them being capable of specific inte-
raction with Fc-fragments of antibodies [5]. One SPA
molecule is capable of binding at least two IgG
molecules. In spite of the application of alternative low
molecular synthetic ligands with some selectivity to
IgG for the purification of antibodies, the degree of
purification with these ligands is considerably lower
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compared to SPA. None of known low molecular
ligands ensures such universal features during the
purification of antibodies as SPA [6].
The advantages of SPA as a bioligand in the
biotechnology are  conformational resistance to the
impact of physical and chemical factors and proteases, 
preservation of functional features in a  wide pH
spectrum (2.0–11.0), a  possibility of renaturation after
the treatment with denaturating solutions of urine
(urea) or guanidine hydrochloride, and the absence of
cysteine residues in its composition which facilitates
the isolation and purification of SPA [7]. Besides, high
affinity to Fc-fragments of antibodies and stability
compared to other immunoglobulin-binding proteins,
used in biotechnology (Streptococcal protein G and
protein L from Peptostreptococcus magnus), allow
positioning SPA as an efficient ligand for the
purification of antibodies in laboratory conditions and
in industrial scale [3, 8].
Different strategies of immobilization of protein li-
gands, SPA in particular, are used while creating affi-
nity sorbents on chromatographic matrices. A classic
method is indirect immobilization of chemically acti-
vated matrices (activation with bromine cyan, carbonyl 
diimidazol, N-hydroxysuccinimide). However, the
application of these matrices often leads to a non-spe-
cific immobilization of a ligand and partial loss of its
functional activity [9]. Besides, the demand for
sorbents of similar kind is restricted by their high cost.
An alternative of immobilization of chemically
activated matrices is genetic engineering introduction
of the cellulose binding domain (CBD) from the
cellulolytic complex of Clostridium thermocellum as a
protein-partner into the composition of SPA sequence
which is capable of specific interaction with carbohy-
drate structure of cellulose. It   ensures targeted immo-
bilization of protein on the matrix and exposure of acti-
ve binding centers in the position, optimal for the inte-
raction with immunoglobulins [10, 11]. This allows
avoiding difficulties, arising during the application of
chemically activated matrices.
The work describes the obtaining of bioaffinity
sorbent on the basis of targeted immobilized SPA with
the help of two cellulose-binding domains and its use
for the purification of antibodies.
Materials and Methods. The strains of
Escherichia coli XL1-blue, BL21 (DE3) and plasmid
vectors pJET1.2 (Fermentas, Lithuania), pGEM-11Zf
(Promega, USA), ðET-24 (Novagen, USA) were used
in the work.
The sequences of oligonucleotides for the ampli-
fication of DNA SPA and CBD (Gene Bank Accession
N X68233) were calculated using Vector NTI program
(Invitrogen, USA) by homology with the known nuc-
leotide sequence, presented in the database of Gen-
Bank BLAST of the National Center of Biotechnolo-
gical Information (NCBI). The oligonucleotides were
synthesized by Syntol company (Russian Federation).
Construction of expression vector pET-24-SPA-
CBD2. The genetically engineered tandem CBD-CBD
was obtained using plasmid pCBD, kindly provided for 
our research by Professor Y. Shoham (Israel). PCR-
amplification of the CBD-CBD sequence was condu-
cted using two pairs of specific primers: 
1) sn1: 5’-CATGCGGCCGCAGGCGGTGTCCG
AAGGCGGTGGCAGCGAAGGTGGCGGCGCAAA
TACACCGGTATCAGG-3’, asn2: 5’-GTGGGATCC
GGGTTCTTTACCCCATACAAGAACAC-3’; 
2)sn3:5’-CATGGATCCGGCGGTGGCTCCGAA
GGCGGTGGCAGCGAAGGTGGCGGCGCAAATA
CACCGGTATCAGG-3’,asn4:5’-GTGCTCGAGGG
GTTCTTT ACCCCATACAAGAACAC-3’.
The first pair of primers was used to introduce the
sequence of linker “-Gly3-Ser-Glu-Gly3-Ser-Glu-
Gly3-” and restriction sites BamHI at the 5’-end and
XhoI – at the 3’-end into the DNA composition of one
CBD: PCR-product 1. The second pair was used to
build the same sequence of linker as well as recognition 
sites for endonucleases of restriction NotI at the 5’-end
and BamHI – at the 3’-end into the composition of the
second CBD: PCR-product 2. PCR-products 1 and 2
(534 b.p. each) were hydrolyzed with the corre-
sponding restrictases and cloned into plasmid vector
pGEM-11Zf with the obtaining of plasmid pGEM-11Zf
(CBD2), further hydrolyzed with restrictases NotI and
XhoI to obtain the fragment CBD-CBD. The latter was
ligated with plasmid vector for the expression of pET24
and construction of plasmid pET-24-CBD2.
DNA-sequence of SPA was amplified from
chromosome DNA of S. aureus.
The following pair of primers was used for PCR:
Sn-SPÀ:
5’-ATCATATGGCGCAACACGATGAAGCTCAA
C-3’ and Asn-SPÀ: 5’-ATGCGGCCGCTTCCT CTTT 
TGGTGC-3’, which were used to introduce restriction
sites NdeI and NotI into the composition of SPA
sequence.
The purified product of SPA amplification (~880
b.p.) was subcloned into the plasmid vector pET-24-
CBD2, which was used to transform E. coli cells, BL21
strain (DE3).
Synthesis of SPA-CBD2. Recombinant SPA-CBD2
was expressed in E. coli cells in accordance to the mo-
dified protocol of autoinduction [12]. The localization
of SPA-CBD2 was determined by the separation of
soluble and insoluble fractions of cell proteins in 12%
SDS PAGE [13].
The analysis of binding SPA-CBD2 to different ty-
pes of polysaccharide matrices. To bind fibrous cellu-
loses (CFI, CFII), microcrystal granular cellulose
(CC31) (Whatman, Great Britain) and chitin (New Eng- 
land BioLabs, Great Britain), the aliquotes of SPA-
CBD2 (100 µl) were incubated for 1 h with the above
mentioned matrices (20 µl), precipitated by centri-
fugation, washed with distilled water and analyzed in
12% SDS PAGE.
To obtain bioaffinity sorbent, SPA-CBD2 was im-
mobilized on microcrystalline cellulose CC31. Then
the sorbent was washed off non-specifically bound
proteins with the buffer (500 mM NaCl, 1 mM EDTA,
20 mM tris-HCl, pH 8.0) and kept at 4°Ñ in 20%
solution of ethanol.
The purification of polyclonal antibodies using the
bioaffinity sorbent. Blood sera of immunized mice,
diluted with the equilibration buffer,  was added to the
chromatographic column, containing 1 ml of bio-
affinity sorbent, which was equilibrated with PBS
buffer (50 mM Na2HPO4, 150 mM NaCl, pH 8.0). The
rate of buffer flow was 0.5 ml per min. The sorbent was
washed with PBS buffer, bound antibodies were eluted
by 0.1 M Na-citrate buffer, pH 3.8. The purity of eluted
antibodies was analyzed by electrophoresis in 12%
SDS PAGE.
ELISA. The antigen rhIFN-a2b (recombinant hu-
man interferon a2b), provided by scientific and indu-
strial complex FarmBiotek (Ukraine), was immo-
bilized in vials of polystirol plate (10 µg/ml) (Nunc,
Denmark). After blocking the sites of non-specific
binding the vials were introduced using polyclonal
antibodies to rhIFN-a2b, previously purified on
bioaffinity sorbent, and incubated for 1 h at 37°Ñ.
Immune complexes were detected using secondary
anti-mouse antibodies (IMTEK, Russian Federation),
conjugated with horseradish peroxidase. TMB solution 
(Sigma, USA) was used as a chromogenic substrate.
Statistical processing of results was conducted with the
application of Origin 7.0 software package.
The application of bioaffinity sorbent for fracti-
onation of mouse IgG. The chromatographic column,
containing 1 ml of bioaffinity sorbent, was connected
to the automated FPLC system (Pharmacia, USA). The 
column was equilibrated by the binding buffer (1.5 M
glycine, 3 M NaCl, pH 8.9) and blood sera of mice, di-
luted with the same buffer, was applied. The rate of bu-
ffer flow was 0.5 ml per min. The sorbent was washed
with the binding buffer before application.  The bound
antibodies were eluted using the following solutions:
0.1 M Na-phosphate, pH 6.0; 0.1 M Na-citrate, pH 4.5
and 0.1 M Na-citrate, pH 3.5. The purity and
concentration of antibodies, obtained after the elution,
were analyzed by electrophoresis in 12% SDS PAGE.
IsoQuick Kit for Mouse Monoclonal Isotyping
(Sigma) was used to determine isotypes of IgG.
Results and Discussion. The criterion, deter-
mining the sorbent capacity, is the density of a ligand
set on the matrix. Here the dynamic capacity of the
sorbent is conditioned by the ligand orientation and
availability of its active center. Therefore, the most
reasonable method is  a direct immobilization of the
ligand, namely,  the introduction of an additional
thiogroup or adapter molecule into the composition of
the protein ligand at the gene level [14, 15].
The adapter protein CBD, isolated from cellulolitic
complex of C. thermocellum, providing for affinity
binding of the protein on the polysaccharide matrix,
was used for SPA immobilization in this work [10]. To
obtain a fusion protein SPA-CBD2 by genetic
engineering, the interactive design was conducted in
accordance to specificities of the structure of proteins-
partners and the topology of their active centers [16,
17]. It was determined that the optimal design of the
chimeric protein presupposes SPA at the N-end and
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two CBD with flexible linker sequences – at the C-end:
“-Gly3-Ser-Glu-Gly3-Ser-Glu-Gly3-”. This relation-
ship ensures spatial availability of immunoglobulin-
binding centers of SPA for the interaction with
Fc-domains of antibodies. The introduction of two
CBD sequences, instead of one, into the composition of 
recombinant protein is conditioned by the necessity of
enhancing the affinity of binding   the recombinant
protein SPA-CBD2 to cellulose [18]. C-terminal
sequence of oligohistidine tag 6His-tag was introduced
into the composition of SPA-CBD2 to perform its
chromatographic purification (Fig.1, a).
To create recombinant protein SPA-CBD2, the
DNA-sequence, encoding SPA, was amplified from
chromosome DNA of S. aureus. The size of the am-
plified DNA fragment is 880 b.p. which corresponds to
the aminoacid sequence of SPA five domains. The
sequenation revealed its complete correspondence to
SPA sequence, presented in the database of GenBank
(Accession N EU695225.1) NCBI. The isolated DNA
sequence, coding for SPA, was subcloned into plasmid
vector pET-24-CBD2, which was used to transform
E. coli, BL21 strain (DE3). It is noteworthy that the
producer of recombinant protein SPA-CBD2 (E. coli,
BL21 strain (DE3)), obtained by us, was sufficiently
stable during long-term storage (at least one year).
Protein SPA-CBD2 was obtained by bacterial
expression according to the modified protocol of
autoinduction. It was determined that SPA-CBD2 is
accumulated in the cytoplasm in soluble form (Fig. 1,
b). The level of its expression is ~ 0,5 g/l (Fig.1, b) of
E. coli culture, which is 80 times higher than in the
work of Shoseyov et al. [19]. The results of CBD bin-
ding to cellulose and SPA binding to immunoglobu-
lins demonstrated functional activity of both partner
proteins   SPA-CBD2.
The next stage of our work was the selection of
chromatographic matrix for the creation of bioaffinity
sorbent. Since CBD has affinity to cellulose, different
types of cellulose (microcrystalline and fibrous) as well 
as chitin were used for the analysis of binding. The
binding experiments demonstrated that the capacity of
SPA-CBD2 for these sorbents fluctuates in the range
from 0.4 (for CFI) to 1.2–1.5 mg/ml (for CC31 and
chitin) (Fig.2). Based on these facts, for obtaining
bioaffinity sorbent SPA-CBD2 was immobilized on
cellulose CC31 and chitin.
The literature data show that the affinity interaction 
of CBD and cellulose leads to the formation of a stable
complex. It occurs due to hydrophobic interactions of
several aminoacid residues of the domain with
carbohydrate structure of cellulose matrix [17]. It was
previously shown that one of the disadvantages of
bioaffinity method of immobilizing hybrid protein on
the matrix is partial dissociation of the complex in acid
conditions (pH 3.0) and its enhancement at further
decrease of pH to 2.0. The latter results in lower purity
of the final product and narrower range of possible
conditions of elution [11]. The solution of this problem
was found in the introduction of genetically engineered 
tandem CBD-CBD into the composition of the hybrid
protein SPA-CBD2 which allowed enhancing its
binding to the matrix [18].
The next required step was the determination of the
conditions of elution, ensuring selective dissociation of 
antibodies and avoiding the leaking of the ligand. The
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Fig.1 Schematic presentation of the cassette
for the expression of recombinant fusion
protein SPA-CBD2 (a) and the
electrophoregram of lysates of E. coli cells
where the synthesis of SPA-CBD2 was
induced (b: 1 – total lysate of proteins of
producent cells; 2 – fraction of insoluble
proteins of the cell; 3 – fraction of soluble
proteins of the cell; 4 – proteins-markers of
molecular mass). 20 µl of culture were
applied to each line.
following solutions were used for elution: 0.1 Ì
glycine, ðÍ 3.0; 0.1 Ì Na-citrate buffer, ðÍ 3.8 and 2
Ì arginine, ðÍ 4.3 [20]. After  electrophoretic
separation of obtained eluates it was determined that
only 2 M arginine causes a considerable leaking of
immobilized SPA-CBD2 into the eluate. While using
glycine and citrate buffer the end product is completely
eluted with a high degree of purity. Based on this fact,
further purification was conducted with the citrate
buffer, pH 3.8 (Fig.3).
The obtained bioaffinity sorbent was used for
isolation of antibodies from blood sera and ascite fluid
of mice (the data are not presented). For this reason 3
ml of 30% suspension of CC31-SPA-CBD2 were
introduced into the 1 ml analytical column. After the
equilibration of the sorbent with phosphate saline
solution we applied diluted sera of mice, immunized
with recombinant IFN-á2b, washed from
non-specifically bound proteins, and eluted the
antibodies with Na-citrate buffer, pH 3.8. As a result
IgG of high  purity (more than 95%) was obtained
(Fig.4). The dynamic capacity of bioaffinity column
for binding antibodies was determined by the
concentration of isolated antibodies. It was found to be
3 mg of mouse antibodies per 1 ml of precipitated
bioaffinity sorbent. Also we established the constancy
of functional characteristics of the bioaffinity sorbent
while storing during one year at 4°Ñ and the possibility
of its repeated application for several cycles of the  
isolation of antibodies without decreasing the dynamic
volume.
The study on the formation of the protein A
-immunoglobulin complex demonstrated that the main
role in SPA binding to IgG is attributed to hydrophobic
interactions between á-helix I of SPA and Fc-domains
of IgG (over 80% of free energy of binding) while the
selectivity of SPA to different subclasses of IgG is
determined by electrostatic interactions between
á-helix II of SPA and Fc-domains of IgG (20%) [21].
Therefore, the application of buffer solutions with high
salt concentration for the binding of IgGs to the column 
promotes their more complete binding to SPA. It
should be noted that IgG from SPA-based sorbents are
eluted in milder conditions comparing with the
application of other affinity sorbents (for instance,
sorbents with immobilized protein G). It ensures
obtaining pure fractions of immunoglobulins without
significant loss of their functional activity. 
Considering  different affinity of SPA to specific
isotypes of murine IgG, the latter were fractioned into
subclasses by means of alternate diminution of pH
value of the elution buffer: IgG1 was eluted at pH 6.0;
IgG-2a – pH 4.5; IgG-2b – pH 3.5 (Fig.5). The
presence of predominantly specific subclasses of
murine IgG was confirmed using IsoQuick Kit for
Mouse Monoclonal Isotyping. It is also known that
human IgG1, IgG2, IgG4 interact with SPA with the
affinity constant ÊÀ = 10
8 Ì–1, while IgG3 demonstra-
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35 →
Fig.2 Electrophoregram of SPA-CBD2 after binding to different types
of polysaccharide matrices: 1 – proteins-markers of molecular mass; 2, 
3 – fibrillar cellulose CFI and CFII, respectively; 4 – microcrystalline
cellulose CC31; 5 – chitin. 3 µl of sorbent were introduced to each line
1      2     3    4  
70 →
kDa
55 →
35→
25 →
←Immunoglobulin
heavy chains
← Immunoglobulin
light chains
Fig.3 Electrophoregram of fractions of antibodies, purified on the
bioaffinity sorbent, obtained during elution with buffer solutions with
different pH values: 1 – proteins-markers of molecular mass; 2 –
elution with Na-citrate buffer, pH 3.8; 3 – elution with glycine buffer,
pH 3.0; 4 – elution with 2 M arginine, pH 4.3
tes weak binding to SPA. It allows distinguishing IgG3
among the other subclasses of human immunoglo-
bulins G.
Conclusions. The results obtained testify to the
promising perspective of applying the bioaffinity sor-
bent, constructed by us, for   highly efficient purifica-
tion and fractionation of poly- and monoclonal
antibodies from the complex biological mixtures in
laboratory conditions. The antibodies, purified on the
bioaffinity sorbent, demonstrated their stability during
storing and sufficient sensitivity for the detection of
corresponding antigens by ELISA method (Fig.6).
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Fig.4 Isolation of polyclonal antibodies against human IFN-α2b from blood sera of immunized mice on the bioaffinity sorbent: a – chromatogram
(1 – application of proteins of blood sera of immunized mice; 2 – proteins, eliminated during the sorbent washing; 3 – elution of bound antibodies); 
b – electrophoregram of protein fractions (1 – application of proteins of blood sera of immunized mice; 2 – proteins, eliminated during the sorbent
washing; 3 – chromatographically purified fraction of polyclonal antibodies against human IFN-α2b; 4 – markers of molecular mass)
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Fig.5 Fractionation of mouse IgG subclasses on the bioaffinity sorbent: a – chromatogram (1 – application of proteins of blood sera; 2 – proteins,
eliminated during the sorbent washing with the buffer; 3–5 – elution of bound antibodies with buffer solutions, containing 0.1 M Na-phosphate,
pH 6.0 (3); 0.1 M Na-citrate, pH 4.5 (4) and 0.1 M Na-citrate, pH 3.5 (5)); b – electrophoregram of protein fractions (1 – application of proteins of
blood sera of immunized mice; 2–4 – purified fractions of antibodies, obtained after gradient elution; 5 – markers of molecular mass)
Besides, cellulose is a cheap and available material,
which does not require additional chemical modi-
fications, that is  another evidence of appropriateness
of the presented investigation.
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Áè î àô ôèí íûé ñî ðáåíò íà îñíî âå èì ìî áè ëè çî âàí íî ãî
áåë êà À Staphylococcus aureus: ñî çäà íèå è èñ ïîëü çî âà íèå
Êè åâ ñêèé íà öè î íàëü íûé óíè âåð ñè òåò èìå íè Òà ðà ñà Øåâ ÷åí êî
Óë. Âëà äè ìèð ñêàÿ, 64, Êèåâ, Óêðà è íà, 01033 
1Èíñòè òóò ìî ëå êó ëÿð íîé áè î ëî ãèè è ãå íå òè êè ÍÀÍ Óêðà è íû
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Sammary
Öåëü. Ñîç äà íèå áè î àô ôèí íî ãî ñî ðáåí òà íà îñíî âå îðè åí òè ðî -
âàí íî èì ìî áè ëè çî âàí íî ãî áåë êà À Sta- phylococcus aureus (SPA)
÷å ðåç äâà öåë ëþ ëî çîñ âÿ çû âà þ ùèõ äî ìå íà (ÑBD) Clostridium
thermocellum  è åãî ïðè ìå íå íèå äëÿ î÷èñ òêè àí òè òåë. Ìå òî äû. Ñ
èñ ïîëü çî âà íè åì ïî ñëå äî âà òåëü íîñ òåé ÄÍÊ, êî äè ðó þ ùèõ SPA è
äâà ÑBD, ñêî íñòðó è ðî âàí ãåí ñëèò íî ãî áåë êà SPA-CBD2 è îá åñ ïå -
÷å íî åãî ïî ëó ÷å íèå â ðàñ òâî ðè ìîé ôîð ìå ýêñ ïðåñ ñè åé â êëåò êàõ
Escherichia coli. Öå ëå âîé áå ëîê èì ìî áè ëè çî âà ëè ìå òî äîì áè î àô -
ôèí íî ãî ñâÿ çûâ íèÿ íà ìèê ðîê ðèñ òàë ëè ÷åñ êîé öåë ëþ ëî çå. Ðå çóëü -
òà òû. Óñòà íîâ ëå íû òà êèå õà ðàê òå ðè- ñòè êè áè î àô ôèí íî ãî
ñî ðáåí òà, êàê åì êîñòü (1 ìã SPA-CBD2 /1 ìë öåë ëþ ëî çè), äè íà ìè -
÷åñ êàÿ åì êîñòü (3 ìã èì ìó íîã ëî áó ëè íîâ ìûøè/1 ìë ñî ðáåí òà) è
ïðî äóê òèâ íîñòü, à òàê æå ïî êà çà íà åãî ñòà áèëü íîñòü ïðè äîë -
ãîñ ðî÷ íîì õðà íå íèè. Ñ ïî ìîùüþ áè î àô ôèí íî ãî ñî ðáåí òà âû äå -
ëå íû ôðàê öèè èì ìó íîã ëî áó ëè íîâ ñ ÷èñ òî òîé áî ëåå 95 %.
Îïðå äå ëå íî, ÷òî î÷è ùåí íûå òà êèì ñïî ñî áîì àí òè òå ëà ñ âû ñî -
êîé ÷ó âñòâè òåëü íîñ òüþ âû ÿâ ëÿ þò ñî îò âå òñòâó þ ùèå àí òè ãå -
íû. Âû âî äû. Ïðåä ëî æåí íûé áè î àô ôèí íûé ñî ðáåíò ïî çâî ëÿ åò
ïî ëó ÷àòü î÷è ùåí íûå ôóíê öè î íàëü íî àê òèâ íûå ïîëè- è ìî íîê ëî -
íàëü íûå àí òè òå ëà, à òàê æå ïðî âî äèòü ôðàê öè î íè ðî âà íèå íà
ïîä êëàñ ñû èì ìó íîã ëî áó ëè íîâ G ìûøè.
Êëþ ÷å âûå ñëî âà: àí òè òå ëà, áå ëîê À, öåë ëþ ëî çîñ âÿ çû âà þ ùèé
äî ìåí, èì ìî áè ëè çà öèÿ áåë êà, àô ôèí íàÿ õðî ìà òîã ðà ôèÿ.
Î. Á. Ãîð áà òþê, Ì. Â. Öà ïåí êî, Ì. Â. Ïàâ ëî âà, Î. Â. Îêóíºâ, 
Â. À. Êîð äþì
Á³îàôô³ííèé ñî ðáåíò íà îñíîâ³  ³ììîá³ë³çî âà íî ãî á³ëêà
À Staphylococcus aureus: ñòâî ðåí íÿ ³ âè êî ðèñ òàí íÿ
Ðå çþ ìå
Ìåòà. Ñòâî ðåí íÿ á³îàô³ííî ãî ñî ðáåí òà íà îñíîâ³ îð³ºíòî âà íî
³ììîá³ë³çî âà íî ãî á³ëêà À Staphylococcus aureus (SPA) ÷å ðåç äâà öå -
ëþ ëî çîç â’ÿ çó âàëü íèõ äî ìå íè (ÑBD) Clostridium thermocellum òà
éîãî çà ñòî ñó âàí íÿ äëÿ î÷è ùåí íÿ àí òèò³ë. Ìå òî äè. Ç âè êî ðèñ -
òàí íÿì ïîñë³äîâ íîñ òåé ÄÍÊ, êî äó þ ÷èõ SPA ³ äâà ÑBD, ñêî íñòðó -
éî âà íî ãåí çëè òî ãî á³ëêà SPA-CBD2 òà çà áåç ïå ÷å íî éîãî îòðè-
ìàí íÿ â ðîç ÷èíí³é ôîðì³ åêñïðåñ³ºþ ó êë³òè íàõ Escherichia coli.
Ö³ëüî âèé á³ëîê ³ììîá³ë³çî âà íî ìå òî äîì á³îàô³ííî ãî çâ’ÿ çó âàí íÿ
íà ì³êðîê ðèñ òàë³÷í³é öå ëþ ëîç³. Ðå çóëü òà òè. Âñòà íîâ ëå íî òàê³
õà ðàê òå ðèñ òè êè á³îàô³ííî ãî ñî ðáåí òà, ÿê ºìí³ñòü (1 ìã SPA-
CBD2/1 ìë öå ëþ ëî çè), äè íàì³÷íà ºìí³ñòü (3 ìã ³ìó íîã ëî áóë³í³â ìè-
ø³/1 ìë ñî ðáåí òà) ³ ïðîäóê òèâí³ñòü, à òà êîæ ïî êà çà íî éîãî
ñòàá³ëüí³ñòü ïðè òðè âà ëî ìó çáåð³ãàíí³. Çà äî ïî ìî ãîþ á³îàô³ííî ãî 
ñî ðáåí òà âèä³ëåíî ôðàêö³¿ ³ìó íîã ëî áóë³í³â ç ÷èñ òî òîþ ïî íàä 95 %. 
Âèç íà ÷å íî, ùî î÷è ùåí³ ó òà êèé ñïîñ³á àí òèò³ëà ç âè ñî êîþ ÷óò -
ëèâ³ñòþ âè ÿâ ëÿ þòü â³äïîâ³äí³ àí òè ãå íè. Âèñ íîâ êè. Çàï ðî ïî íî âà -
íèé á³îàô³ííèé ñî ðáåíò äîç âî ëÿº îò ðè ìó âà òè î÷è ùåí³ ôóíê-
ö³îíàëü íî àê òèâí³ ïîë³- ³ ìî íîê ëî íàëüí³ àíòò³ëà, à òà êîæ ïðî âî -
äè òè ôðàêö³îíó âàí íÿ íà ï³äêëà ñè ³ìó íîã ëî áóë³í³â G ìèø³.
Êëþ ÷îâ³ ñëî âà: àí òèò³ëà, á³ëîê À, öå ëþ ëî çîç â’ÿ çó âàëü íèé äî -
ìåí, ³ììîá³ë³çàö³ÿ á³ëêà, àô³ííà õðî ìà òîã ðàô³ÿ.
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